Rachel-Karson Thériault

Rachel-Karson Thériault

Auto-generated profile, based on publicly available information

Rachel-Karson Thériault

Department of Molecular and Cellular Biology, University of Guelph, Ontario, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Neuroscience
Verified
Journal Article
Closed access
JMJoshua D. Manduca
Joshua D. Manduca
RTRachel-Karson Thériault
Rachel-Karson Thériault
OWOlivia Williams
Olivia Williams
DRDuncan J. Rasmussen
Duncan J. Rasmussen
MPMelissa Perreault
Melissa Perreault

1 April 2022 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
AKAdrian Kilcoyne
Adrian Kilcoyne
EJEdward Jordan
Edward Jordan
KTKimberly Thomas
Kimberly Thomas
APAlicia N Pepper
Alicia N Pepper
AZAllen Zhou
Allen Zhou
MTMelissa Thompson
Melissa Thompson
Purpose: To estimate the clinical and economic benefits of lenzilumab plus standard of care (SOC) compared with SOC alone in the treatment of hospitalized COVID-19 patients from the National Health Service (NHS) England perspective. Methods: A cost calculator was developed to estimate the clinical benefits and costs of adding lenzilumab to SOC in newly hospitalized COVID-19 patients over 28 days. The LIVE-AIR trial results informed the clinical inputs: failure to achieve survival without ventilation (SWOV), mortality, time to recovery, intensive care unit (ICU) admission, and invasive mechanical ventilation (IMV) use. Base case costs included drug acquisition and administration for lenzilumab and remdesivir and hospital resource costs based on the level of care required. Clinical and economic benefits per weekly cohort of newly hospitalized patients were also estimated. Results: In all populations examined, specified clinical outcomes were improved with lenzilumab plus SOC over SOC treatment alone. In a base case population aged < 85 years with C-reactive protein (CRP) < 150 mg/L, with or without remdesivir, adding lenzilumab to SOC was estimated to result in per-patient cost savings of £ 1162. In a weekly cohort of 4754 newly hospitalized patients, addition of lenzilumab to SOC could result in 599 IMV uses avoided, 352 additional lives saved, and over £ 5.5 million in cost savings. Scenario results for per-patient cost savings included: 1) aged < 85 years, CRP < 150 mg/L, and receiving remdesivir (£ 3127); 2) Black patients with CRP < 150 mg/L (£ 9977); and 3) Black patients from the full population (£ 2369). Conversely, in the full mITT population, results estimated additional cost of £ 4005 per patient. Conclusion: Findings support clinical benefits for SWOV, mortality, time to recovery, time in ICU, time on IMV, and ventilator use, and an economic benefit from the NHS England perspective when adding lenzilumab to SOC for hospitalized COVID-19 patients.

20 April 2024 in Schizophrenia Research
Verified
Journal Article
Open access
AAAbdalla M. Albeely
Abdalla M. Albeely
OWOlivia Williams
Olivia Williams
CBColin R. Blight
Colin R. Blight
RTRachel-Karson Thériault
Rachel-Karson Thériault
MPMelissa Perreault
Melissa Perreault
The methylazoxymethanol acetate (MAM) rodent model is used to study aspects of schizophrenia. However, numerous studies that have employed this model have used only males, resulting in a dearth of knowledge on sex differences in brain function and behaviour. The purpose of this study was to determine whether differences exist between male and female MAM rats in neuronal oscillatory function within and between the prefrontal cortex (PFC), ventral hippocampus (vHIP) and thalamus, behaviour, and in proteins linked to schizophrenia neuropathology. We showed that female MAM animals exhibited region-specific alterations in theta power, elevated low and high gamma power in all regions, and elevated PFC-thalamus high gamma coherence. Male MAM rats had elevated beta and low gamma power in PFC, and elevated vHIP-thalamus coherence. MAM females displayed impaired reversal learning whereas MAM males showed impairments in spatial memory. Glycogen synthase kinase-3 (GSK-3) was altered in the thalamus, with female MAM rats displaying elevated GSK-3α phosphorylation. Male MAM rats showed higher expression and phosphorylation GSK-3α, and higher expression of GSK-β. Sex-specific changes in phosphorylated Tau levels were observed in a region-specific manner. These findings demonstrate there are notable sex differences in behaviour, oscillatory network function, and GSK-3 signaling in MAM rats, thus highlighting the importance of inclusion of both sexes when using this model to study schizophrenia.